Home > Healthcare > Medical Devices > Diagnostic Devices > Radiotheranostics Market

Radiotheranostics Market Share

Report ID: GMI8785
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Radiotheranostics Market Share

The radiotheranostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Radiotheranostics Market Companies

Some of the eminent market participants operating in the radiotheranostics industry include:

Life Healthcare Group
Nordic Nanovector ASA
Novartis AG
Progenics Pharmaceuticals, Inc.
Q BioMed Inc.
QSAM Biosciences, Inc.
RadioMedix
Radiopharm Theranostics Limited
Telix Pharmaceuticals Limited
Terumo Corporation

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global radiotheranostics industry reached USD 2 billion in 2023 and is estimated to record over USD 6.6 billion by 2032, driven by the growing use of radiotheranostics in cancer diagnostics.

The targeted therapeutics approach segment in the market a decent share in 2023 and is expected to reach USD 4 billion by 2032, driven by personalized treatments leading to more effective outcomes.

North America radiotheranostics industry accounted for USD 798.3 million in revenue in 2023 and is predicted to witness substantial growth over the analysis timeline, owing to a well-developed healthcare infrastructure.

Life Healthcare Group, Nordic Nanovector ASA, Novartis AG, Progenics Pharmaceuticals, Inc, Q BioMed Inc., QSAM Biosciences, Inc., RadioMedix, Radiopharm Theranostics Limited among others